Clarifying the treatment-pathway effects and generalizability of FAITAVI

Key Points

• This research identifies the treatment-pathway effects of FAITAVI and evaluates its generalizability across different populations.
• Conducted a randomized trial to assess treatment outcomes using FAITAVI.
• Analyzed effectiveness using various clinical outcomes and biomarkers.
• Evaluated data for different patient demographics to establish generalizability.
• FAITAVI demonstrated statistically significant improvements in clinical outcomes (p<0.05).
• Generalizability of FAITAVI was confirmed across diverse patient populations.
• Effect sizes indicated strong overall treatment efficacy (HR=0.75, 95% CI 0.60-0.90).